TG Therapeutics Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for TG Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TG Therapeutics stock.
View analyst ratings for TG Therapeutics or view top-rated stocks.

Wall Street analysts have given TG Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but TG Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

TG Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for TG Therapeutics.

TG Therapeutics, Inc. (NASDAQ:TGTX) announced its earnings results on Monday, May, 10th. The biopharmaceutical company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.17. The biopharmaceutical company earned $0.79 million during the quarter, compared to analyst estimates of $0.99 million. TG Therapeutics had a negative trailing twelve-month return on equity of 95.94% and a negative net margin of 35,158.99%.
View TG Therapeutics' earnings history.

TG Therapeutics' stock was trading at $10.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TGTX shares have increased by 277.9% and is now trading at $37.83.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 12 month price targets for TG Therapeutics' shares. Their forecasts range from $38.00 to $95.00. On average, they expect TG Therapeutics' stock price to reach $64.00 in the next twelve months. This suggests a possible upside of 69.2% from the stock's current price.
View analysts' price targets for TG Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to TG Therapeutics include UCB (UCBJF), Catalent (CTLT), Elanco Animal Health (ELAN), Viatris (VTRS), Zai Lab (ZLAB), BioMarin Pharmaceutical (BMRN), Dr. Reddy's Laboratories (RDY), Ono Pharmaceutical (OPHLF), Maravai LifeSciences (MRVI), Grifols (GRFS), Bausch Health Companies (BHC), CureVac (CVAC), Jazz Pharmaceuticals (JAZZ), Teva Pharmaceutical Industries (TEVA) and BridgeBio Pharma (BBIO).
View all of TGTX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other TG Therapeutics investors own include Novavax (NVAX), AK Steel (AKS), Micron Technology (MU), Cara Therapeutics (CARA), Gilead Sciences (GILD), UrtheCast (UR), Verastem (VSTM), BioDelivery Sciences International (BDSI), Sorrento Therapeutics (SRNE) and Corbus Pharmaceuticals (CRBP).

TG Therapeutics trades on the NASDAQ under the ticker symbol "TGTX."

Shares of TGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TGTX stock can currently be purchased for approximately $37.83.

TG Therapeutics has a market capitalization of $5.35 billion and generates $150,000.00 in revenue each year. The biopharmaceutical company earns $-279,380,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

TG Therapeutics employs 147,000 workers across the globe.

The official website for TG Therapeutics is www.tgtherapeutics.com.

TG Therapeutics is headquartered at 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014.

TG Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at (212) 554-4484 or via email at [email protected]